Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women.

ABSTRACT:

Introduction and hypothesis

Mirabegron, a beta-3 agonist, is prescribed for urgency urinary incontinence (UUI). We assessed the correlation of symptom improvement with urobiome characteristics in adult women participants prescribed mirabegron for UUI treatment.

Methods

We enrolled participants seeking UUI treatment who selected mirabegron and agreed to participate in this 12-week, open label study conducted at the Female Pelvic Medicine and Reconstructive Surgery Center at Loyola University Medical Center. Following eligibility screening and research consent, participants completed the overactive bladder questionnaire (OAB-Q) and provided a catheterized urine sample at baseline, 4, 8, and 12 weeks. The primary outcome, symptom improvement at 12 weeks, was based on the valida

SUBMITTER: Halverson T 

PROVIDER: S-EPMC9119880 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature